- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05973643
Metabolomics During ElectroConvulsivoTherapy (METECT)
Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Biological signatures of blood metabolome will be measure before and after the first session of electroconvulsivetherapy, and during the course, before the 6th, 12th and the last sessions. Proton Nuclear Magnetic Resonance spectroscopy will be used to measure metabolites in blood sample. In parallel, at each time point, depression severity (MADRS and BDI), Perceived severity (CGI), global functioning (EGF), convulsive characteristics and cognitive tolerance (MOCA) will be measure, at each time point.
The aim of this study is to determine whether 1HNMR could help to understanding metabolic ways and predict response to ECT in patients with a current Major Depressive Episode (MDE) in Major Depressive Disorder (MDD) and in Bipolar Disorder (BD).
To date, scientific community knows that ECT is a safety and efficacy treatment in MDE particularly resistant or severe, but scientific community knows little about its mechanism of action.
The investigators hypothesize that 1HNMR could help to go further.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: SARTELET Lydie
- Phone Number: +33 0437915531
- Email: lydie.sartelet@ch-le-vinatier.fr
Study Contact Backup
- Name: COSTEMALE-LACOSTE Jean-François, PH
- Phone Number: +33 (0)4 37 91 54 95
- Email: jean-francois.costemale-lacoste@ch-le-vinatier.fr
Study Locations
-
-
-
Bron, France, 69678
- Centre Hospitalier Le Vinatier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Major depressive episode according to DSM-5 criteria
- Diagnosis of major depressive disorder or bipolar disorder
- MADRS score >22
- having given written, free and informed consent
- without protective measures
- resistance criterion defined as failure of 2 antidepressants at an effective dose for a minimum of 6 weeks
- current major depressive episode according to DSM-5 criteria with indication of treatment by ECT cure
Exclusion Criteria - Cannot be included in the study, people:
- whose consent is not admissible or who refuse to participate in the study
- deprived of liberty by judicial or administrative decision
- For which there is a particular risk contraindicating the cure of ECT
- Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder
- suffering from neurological disorders (such as patients suffering from multiple sclerosis, epilepsy, encephalitis, etc.) and/or neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease or related diseases, etc.) as described by criterion C of the major depressive disorder listed in the DSM-5
- suffering from an acute or chronic systemic inflammatory disease requiring specific treatment with immunomodulators or suppressors. As well as any recurrent inflammatory disease requiring specific management, and which may lead to a differential diagnosis of the characterized depressive episode as described by criterion C listed in the DSM-5
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Electroconvulsive therapy
simple-blind, any adult patient presenting a characterized depressive episode in the context of unipolar major depressive disorder or bipolar disorder who consents and requires an ECT treatment.
study including 50 patients.
|
Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia. The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week. Blood samples will be done during the anesthesia process. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Value the metabolic profile difference between the baseline and before the 6th session of ECT by blood metabolomics through 1HNMR
Time Frame: up to 3 weeks
|
identify variations in the metabolome by measuring the metabolome in the blood of patients treated for depressive episodes or bipolar disorder by identifying the metabolic profiles associated with the medical response to ECT between the Baseline and before the sixth ECT session.
|
up to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the biological effect of one ECT session on the blood metabolome
Time Frame: through first ECT session, an average of 1 week
|
Comparison of quantitative and qualitative measurements of metabolites and metabolic signatures obtained by 1HNMR between baseline and the first ECT by observing either a clinical response or a clinical remission by discriminating remitters and no remitters patients.
|
through first ECT session, an average of 1 week
|
Compare the biological effect measured between the baseline and before the 1st, 6th and 12th session of ECT
Time Frame: through study completion, up to 6 weeks
|
Comparison of quantitative and qualitative measurements of metabolites and metabolic signatures obtained by 1HNMR between baseline and the first ECT by observing either a clinical response or a clinical remission by discriminating remitters and no remitters patients.
The clinical response is defined by the decrease of 50% on the MADRS scale.
The clinical remission is defined by a score less than or equal to 10 on the MADRS scale.
|
through study completion, up to 6 weeks
|
Measure the variations of the metabolic signature according to the clinical response during the ECT treatment
Time Frame: up to 10 weeks
|
Comparison of quantitative and qualitative measures of metabolites taken separately and metabolic signatures obtained by 1H NMR according to the clinical response on the MADRS scale (the overall score thus ranges from 0 to 60) throughout the course of ECT.
The clinical response is defined by the decrease of 50% on the MADRS scale.
The clinical remission is defined by a score less than or equal to 10 on the MADRS scale.
|
up to 10 weeks
|
Look for a metabolic signature to discriminate between responder and non-responder patients before the 6 ECT sessions (i.e. the day of the 6th)
Time Frame: through the sixth session, up 3 weeks
|
Comparison of metabolic signatures obtained by very high field NMR between responder and non-responder patients before the 6th ECT session (V2)
|
through the sixth session, up 3 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14.
- Aberg-Wistedt A, Martensson B, Bertilsson L, Malmgren R. Electroconvulsive Therapy Effects on Cerebrospinal Fluid Monoamine Metabolites and Platelet Serotonin Uptake In Melancholia. Convuls Ther. 1986;2(2):91-98.
- Abrams R, Essman WB, Taylor MA, Fink M. Concentration of 5-hydroxyindoleacetic acid, homovanillic acid, and tryptophan in the cerebrospinal fluid of depressed patients before and after ECT. Biol Psychiatry. 1976 Feb;11(1):85-90.
- van Diermen L, van den Ameele S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, Birkenhager TK. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br J Psychiatry. 2018 Feb;212(2):71-80. doi: 10.1192/bjp.2017.28. Erratum In: Br J Psychiatry. 2018 May;212(5):322.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-A00548-37
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Episode
-
Northside Clinic, AustraliaWesley MissionCompletedMajor Depressive EpisodeAustralia
-
University Hospital, MontpellierRecruitingMajor Depressive EpisodeFrance
-
Medical University of ViennaUnknownMajor Depressive EpisodeAustria
-
The University of New South WalesWesley MissionUnknown
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Jiangsu Province Nanjing Brain HospitalRecruitingMajor Depressive EpisodeChina
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University Medical Center GoettingenCompletedMajor Depressive Disorder | Depressive EpisodeGermany
-
University of British ColumbiaCentre for Addiction and Mental HealthRecruitingDepression | Major Depressive Disorder | Major Depressive EpisodeCanada
-
Milton S. Hershey Medical CenterPatient-Centered Outcomes Research Institute; Health Resources and Services...CompletedMajor Depressive Disorder | Major Depressive EpisodeUnited States
Clinical Trials on Electroconvulsive therapy
-
Medical University of LodzUnknown
-
Haukeland University HospitalHelse Stavanger HFRecruiting
-
Charles University, Czech RepublicRecruitingBipolar Depression | Major Depressive DisorderCzechia
-
Mehmet Diyaddin GülekenUnknown
-
University of Medicine and Dentistry of New JerseyNational Institute of Mental Health (NIMH)CompletedComparison of Three Electroconvulsive Therapy (ECT) Techniques for the Treatment of Major DepressionDepressionUnited States
-
Massachusetts General HospitalRecruitingBipolar Depression | Unipolar DepressionUnited States
-
Haukeland University HospitalUniversity of BergenCompletedDepression | Electroconvulsive Therapy
-
Haukeland University HospitalUniversity of BergenRecruitingHealthy | Major Depressive Disorder | Major Depressive Disorder 1Norway
-
Shanghai Mental Health CenterCompleted
-
Eastern Virginia Medical SchoolSentara Norfolk General HospitalTerminatedSelf-Injurious Behavior | Autism Spectrum DisorderUnited States